Request Demo

Last update 25 Jun 2025

Fentanyl Citrate

Last update 25 Jun 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Abstral Sublingual, E-Fen Buccal, Fentanyl citrate (JP17/USP)

+ [33]

Target

μ opioid receptor

Action

agonists

Mechanism

μ opioid receptor agonists(Mu opioid receptor agonists)

Therapeutic Areas

Nervous System DiseasesUrogenital DiseasesOther Diseases

Active Indication

Breakthrough PainCancer PainHyperemesis Gravidarum+ [1]

Inactive Indication

Anemia, Sickle CellBurnsChronic Pain+ [5]

Originator Organization

Rising Pharmaceuticals, Inc.

Active Organization

Istituto Gentili Srl

Grünenthal GmbHTeva Pharmaceuticals Europe BV

+ [5]

Inactive Organization

Cephalon, Inc.

BioDelivery Sciences International, Inc.BTcP Pharma LLC

+ [6]

License Organization

Kunwha Pharmaceutical Co., Ltd.

Collegium Pharmaceutical, Inc.

Adalvo Ltd.

+ [5]

Drug Highest PhaseApproved

First Approval Date

United States (19 Feb 1968),

Anesthesia

Regulation-

Structure/Sequence

Molecular FormulaC28H36N2O8

InChIKeyIVLVTNPOHDFFCJ-UHFFFAOYSA-N

CAS Registry990-73-8

870

Clinical Trials associated with Fentanyl Citrate

CTRI/2024/12/077557

/ Not yet recruitingNot ApplicableIIT

A Prospective Randomised Comparative Study of 0.5 percent Hyperbaric Levobupivacaine with Fentanyl and 0.5 percent Hyperbaric Bupivacaine with Fentanyl for spinal anesthesia for Caesarean section. - NIL

Start Date18 Sep 2025

Sponsor / Collaborator-

CTRI/2024/10/075044

/ Not yet recruitingNot ApplicableIIT

A comparative study of hyperbaric levobupivacaine 0.5 percentage alone vs hyperbaric levobupivacaine 0.5 percentage with fentanyl in spinal anesthesia for lower abdominal and lower extremity surgeries - NIL

Start Date15 Sep 2025

Sponsor / Collaborator-

NCT06696586

/ Not yet recruitingPhase 4IIT

Comparison Between Effect of Systemic Fentanyl Infusion and Fentanyl Added as An Adjuvant to Lidocaine in Bier Block For Controlling Pain in Patients Undergoing Hand Surgeries

Injury and deformity of the upper extremity can result in dysfunction to nerves, tendons and bones which can lead to disability and pain.
Various techniques of regional anesthesia are frequently used for upper extremity surgery. Specifically, intravenous regional anesthesia, the Bier block, is an effective anesthetic technique. This technique, developed by Dr August Bier in 1908, provides complete anesthesia, a bloodless field, and eliminates the need for general anesthesia. However, it was not until the 1960s that this technique was reintroduced and used in upper extremity surgery due to several disadvantages and reports of major complications. Because of the dose of lidocaine and tourniquet time, there is potential for cardiac and neurological complications such as arrhythmias, seizures, and compartment syndrome the aim of this study To evaluate the effect of Systemic Fentanyl Infusion compared to addition of Fentanyl as An Adjuvant to Lidocaine in Bier Block for Controlling Pain in Patients Undergoing Hand Surgeries

Start Date01 Jul 2025

Sponsor / Collaborator

Assiut University

100 Clinical Results associated with Fentanyl Citrate

100 Translational Medicine associated with Fentanyl Citrate

100 Patents (Medical) associated with Fentanyl Citrate

12,283

Literatures (Medical) associated with Fentanyl Citrate

01 Nov 2025·SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY

A novel label-free carbon dots-based fluorescent aptamer sensor for the detection of fentanyl

Article

Author: Tong, Yishuo ; Yan, Jiangwei ; Niu, Weifen ; Wang, Zheyu ; Liu, Baihui ; Dong, Chuan

Fentanyl, a widely abused potent synthetic opioid, poses a challenge due to its narrow therapeutic window, increasing the risk of overdose and death. Fast, easy, and cost-effective screening for fentanyl in biological samples is crucial for forensic and public safety purposes. We hereby present a label-free fluorescence sensor for the precise and sensitive identification of fentanyl, utilizing carbon dots (CDs) in conjunction with aptamers. By synthesizing green-emitting CDs in a single step using an environmentally friendly method with o-phenylenediamine (OPD) and thiourea in acetone, the CDs displayed excellent optical properties and biocompatibility. Due to the positive charge of CDs, their fluorescence quenching is caused by electrostatic interactions with negatively charged aptamers. When fentanyl is introduced, the specific binding between fentanyl and the fentanyl aptamer is strengthened, resulting in fluorescence recovery. Under optimal experimental conditions, there was a linear relationship between fluorescence intensity and fentanyl concentration in the 5-1000 nM with a limit of determination of 1.90 nM. The robust quantification of fentanyl in complex human saliva matrices achieved by this aptamer-based biosensing platform validates its clinical reliability, particularly for non-invasive point-of-care monitoring and harm-reduction interventions in opioid crisis management.

01 Sep 2025·TALANTA

SERS detection of analgesics in serum based on Ag nanocubes for perioperative monitoring

Article

Author: Qin, Lei ; Ji, Yinghe ; Han, Lin ; Wu, Jing ; Wang, Yunpeng ; Zhu, Zhuo ; Li, Yang ; Sun, Tingting

Prompt and personalized perioperative analgesia management relies on sensitive and convenient monitoring of analgesics. We report a strategy for sensitive and reproducible SERS detection of analgesics based on Ag nanocubes, which have abundant intragranular hot spots on sharp corners and interparticle hot spots between gaps. Both theoretical simulations and R6G detection experiments indicated that the enhancement factor of Ag nanocube SERS platform reach to 10⁶ level. Quantitative and reproducible determination capabilities of this platform for six different analgesics with LOD as low as 500 pg mL^-1 were verified. Pharmacokinetic experiment of fentanyl in rat serum samples by SERS detection within 4 h presented consistent results with the UHPLC-MS/MS method. Valid examples of SERS detection for single or multiple analgesics in clinical patients' serums further proved the feasibility of this platform for perioperative analgesic monitoring.

01 Aug 2025·NEUROPHARMACOLOGY

A putative binding model of nitazene derivatives at the μ-opioid receptor

Article

Author: Shen, Jana ; Robertson, Michael J ; Skiniotis, Georgios ; Michaelides, Michael ; Stavitskaya, Lidiya ; Clayton, Joseph ; Shi, Lei

Nitazenes are a class of novel synthetic opioids with exceptionally high potency. Currently, an experimental structure of μOR-opioid receptor (μOR) in complex with a nitazene is lacking. Here we used a suite of computational tools, including consensus docking, conventional molecular dynamics (MD) and metadynamics simulations, to investigate the μOR binding modes of nitro-containing meto-, eto-, proto-, buto-, and isotonitazenes and nitro-less analogs, metodes-, etodes-, and protodesnitazenes. Docking generated three binding modes, whereby the nitro-substituted or unsubstituted benzimidazole group extends into SP1 (subpocket 1 between transmembrane helix or TM 2 and 3), SP2 (subpocket 2 between TM1, TM2, and TM7) or SP3 (subpocket 3 between TM5 and TM6). Simulations suggest that etonitazene and likely also other nitazenes favor the SP2-binding mode. Comparison to the experimental structures of μOR in complex with BU72, fentanyl, and mitragynine pseudoindoxyl (MP) allows us to propose a putative model for μOR-ligand recognition in which ligand can access hydrophobic SP1 or hydrophilic SP2, mediated by the conformational change of Gln124^2.60. Interestingly, in addition to water-mediated hydrogen bonds, the nitro group in nitazenes forms a π-hole interaction with the conserved Tyr75^1.39. Our computational analysis provides new insights into the mechanism of μOR-opioid recognition, paving the way for investigations of the structure-activity relationships of nitazenes.

News (Medical) associated with Fentanyl Citrate

19 Jun 2025

·www.prnewswire.com

Indivior Presents New Data at CPDD Demonstrating that High Buprenorphine Exposure May Improve Treatment Outcomes in High Fentanyl Users

A post-hoc analysis demonstrates that buprenorphine exposure with 300 mg SUBLOCADE® (buprenorphine extended-release) may improve treatment outcomes among opioid use disorder (OUD) patients with heavy fentanyl use1 Additional Indivior-funded research identified OUD treatment barriers in American Indian/Alaska Native (AI/AN) people who are often affected by higher drug overdose death rates compared to other racial and ethnic groups2-5 RICHMOND, Va., June 19, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV) presented new findings this week at the College on Problems of Drug Dependence (CPDD) Annual Scientific Meeting. A post hoc analysis showed that patients with heavier fentanyl use experienced clinically meaningful improvements in opioid abstinence when treated with a 300 mg maintenance dose of SUBLOCADE, compared to the 100 mg dose. While the 300 mg dose did not demonstrate a statistically significant advantage over 100 mg for weekly abstinence—the study's primary endpoint—in the overall population with moderate to severe opioid use disorder (OUD), the results suggest that higher doses of SUBLOCADE may offer better outcomes for individuals with high levels of fentanyl use. "These findings offer additional evidence that the higher maintenance dose of SUBLOCADE is safe and may better support patients with intense fentanyl use patterns," said Christian Heidbreder, Ph.D., Chief Scientific Officer at Indivior. "We aim to provide clinicians with new data that can transform treatment strategies and support patients on their journey to recovery." In the Indivior-funded study, patients with OUD who engaged in high-risk opioid use—such as injection use, high opioid dose consumption, or fentanyl use—received two initial 300 mg injections of SUBLOCADE one week apart. They were then randomized to receive eight monthly maintenance doses of either 100 mg or 300 mg. Both dosing regimens led to significant reductions in opioid use: the average weekly use dropped sharply from over 40 instances at screening to fewer than 3 by Week 3, and this improvement was sustained through Week 38. Notably, no new safety concerns were identified with either the 100 mg or 300 mg maintenance doses. Indivior also funded research exploring OUD treatment access and outcomes in American Indian/Alaska Native (AI/AN) populations, which were presented at CPDD. AI/AN populations experience disproportionate rates of OUD, drug overdose, and gap in access to OUD care. A thematic analysis of focus group research on nine AI/AN advocates indicated that AI/AN people experience significant barriers to accessing medication for opioid use disorder (MOUD).4-8 Barriers include stigma, institutional challenges, and transitions of care for OUD, highlighting opportunities for culturally appropriate interactive education and institutional advancement.2 These focus group findings are illustrative and can be used to identify avenues for future work, although they may not be generalizable to the full population. In addition, a large multi-year longitudinal claims database analysis of more than 75,000 AI/AN patients with evidence of OUD showed differences in utilization of MOUD among those seeing Indian Health Services (IHS) vs. non-IHS providers. The majority of patients (73.1%) saw non-IHS providers. Patients treated with any form of MOUD had lower all-cause emergency department vs. those who were not treated with MOUD, highlighting the need for further research to understand MOUD utilization among AI/AN. "The collective evidence from these presentations highlights prominent barriers to effective care and helps map out appropriate treatment approaches for individuals with OUD in challenging treatment settings," said Heidbreder. "Indivior focuses its scientific, treatment, and policy efforts on helping patients access the medications and support they need to recover." Key Abstracts Presented at CPDD: Higher Exposures with 300-Mg Buprenorphine Extended-Release (BUP-XR) Increased the Proportion of Responders Among Opioid Use Disorder (OUD) Patients with Heavy Fentanyl Use Barriers to and Facilitators of Medication Treatment for Opioid Use Disorder Identified by American Indian/Alaska Native Advocates Utilization of Medications for Opioid Use Disorder (MOUD) and Patient Profiles Amongst American Indian/Alaska Native Managing Opioid Use Disorder (OUD) Polysubstance Use in Treatment for Opioid Use Disorder: Opioid Abstinence and Alternative Substance Use Clinical Outcomes and Recovery in Adults with Opioid Use Disorder: Long-term Treatment with Long- acting Injectable Buprenorphine under Real-World Conditions Severity and Symptomatology of Opioid Use Disorder (OUD) Among Individuals Reporting Pain Reliever Use, Pain Reliever Misuse, and/or Heroin Use: A Cross-sectional Analysis of the 2021 and 2022 National Survey on Drug Use and Health Disclosure: This press release has been issued by Indivior Inc. and the content has not been approved or authorized by the College on Problems of Drug Dependence. About SUBLOCADE® SUBLOCADE® (buprenorphine extended-release) injection, for subcutaneous use, CIII INDICATION AND HIGHLIGHTED SAFETY INFORMATION INDICATION SUBLOCADE is indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine. SUBLOCADE should be used as part of a complete treatment plan that includes counseling and psychosocial support. HIGHLIGHTED SAFETY INFORMATION WARNING: RISK OF SERIOUS HARM OR DEATH WITH INTRAVENOUS ADMINISTRATION; SUBLOCADE RISK EVALUATION AND MITIGATION STRATEGY Serious harm or death could result if administered intravenously. SUBLOCADE forms a solid mass upon contact with body fluids and may cause occlusion, local tissue damage, and thrombo-embolic events, including life-threatening pulmonary emboli, if administered intravenously. Because of the risk of serious harm or death that could result from intravenous self-administration, SUBLOCADE is only available through a restricted program call the SUBLOCADE REMS Program. Healthcare settings and pharmacies that order and dispense SUBLOCADE must be certified in this program and comply with the REMS requirements. CONTRAINDICATIONS Hypersensitivity to buprenorphine or any other ingredients in SUBLOCADE. WARNINGS AND PRECAUTIONS Addiction, Abuse, and Misuse: SUBLOCADE contains buprenorphine, a Schedule III controlled substance that can be abused in a manner similar to other opioids. Monitor patients for conditions indicative of diversion or progression of opioid dependence and addictive behaviors. Respiratory Depression: Life threatening respiratory depression and death have occurred in association with buprenorphine. Warn patients of the potential danger of self-administration of benzodiazepines or other CNS depressants while under treatment with SUBLOCADE. Risk of Serious Injection Site Reactions: Likelihood of may increase with inadvertent intramuscular or intradermal administration. Evaluate and treat as appropriate. The most common injection site reactions are pain, erythema and pruritus with some involving abscess, ulceration and necrosis. Neonatal Opioid Withdrawal Syndrome: Neonatal opioid withdrawal syndrome (NOWS) is an expected and treatable outcome of prolonged use of opioids during pregnancy. Adrenal Insufficiency: If diagnosed, treat with physiologic replacement of corticosteroids, and wean patient off of the opioid. Risk of Opioid Withdrawal with Abrupt Discontinuation: If treatment with SUBLOCADE is discontinued, monitor patients for several months for withdrawal and treat appropriately. Risk of Hepatitis, Hepatic Events: Monitor liver function tests prior to and during treatment. Risk of Withdrawal in Patients Dependent on Full Agonist Opioids: Verify that patients have tolerated transmucosal buprenorphine before injecting SUBLOCADE. Treatment of Emergent Acute Pain: Treat pain with a non-opioid analgesic whenever possible. If opioid therapy is required, monitor patients closely because higher doses may be required for analgesic effect. ADVERSE REACTIONS Adverse reactions commonly associated with SUBLOCADE (in ≥5% of subjects) were constipation, headache, nausea, injection site pruritus, vomiting, increased hepatic enzymes, fatigue, and injection site pain. For more information about SUBLOCADE, the full Prescribing information including BOXED WARNING, and Medication Guide, visit . About Opioid Use Disorder (OUD) Opioid Use Disorder (OUD) is a chronic disease in which people develop a pattern of using opioids that can lead to negative consequences. OUD may affect the parts of the brain that are necessary for life-sustaining functions. About Indivior Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat opioid use disorder (OUD). Our vision is that all patients around the world will have access to evidence-based treatment for OUD and we are dedicated to transforming OUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to expand on its heritage in this category. Headquartered in the United States in Richmond, VA, Indivior employs over 1,000 individuals globally and its portfolio of products is available in over 30 countries worldwide. Visit to learn more. Connect with Indivior on LinkedIn by visiting . Higher Exposures with 300-Mg Buprenorphine Extended-Release (BUP-XR) Increased the Proportion of Responders Among Opioid Use Disorder (OUD) Patients with Heavy Fentanyl Use [Late Breaking Oral Sessions]. CPDD Annual Scientific Meeting, June 15, 2025. Barriers To and Facilitators Of Medication Treatment for Opioid Use Disorder Identified by American Indian/Alaska Native Advocates [Oral Session: Expanding SUD interventions across populations]. CPDD Annual Scientific Meeting, June 17, 2025. Utilization of Medications for Opioid Use Disorder (MOUD) and Patient Profiles amongst American Indian/Alaska Native Managing Opioid Use Disorder (OUD) [Poster Session 1]. CPDD Annual Scientific Meeting, June 15, 2025. Indian Health Service. Disparities. 2019. Retrieved from . Accessed: 16 May 2024. Centers for Disease Control and Prevention, National Center for Health Statistics (2024). Rate of National Drug Overdose Deaths, By Demographic. Available at: statistics/overdose-death-rates. Accessed: 6 Jun 2024. Soto C, et al. (2022). International Journal of Environmental Research and Public Health, 19(5), 2974. doi:10.3390/ijerph19052974 Krawczyk N, et al. . Drug Alcohol Depend. 2021 Mar 1;220:108512. doi: 10.1016/j.drugalcdep.2021.108512 Mpofu, E, et al.. (2021). Addictive Behaviors, 114, 106743. doi:10.1016/j.addbeh.2020.106743 SOURCE Indivior PLC WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Clinical ResultPhase 3

11 Jun 2025

·www.prnewswire.com

Elysium Therapeutics' Investor Webcast Highlights "Fentanyl Rebound" as Key Challenge in Reducing Opioid Overdose Hospitalizations and Deaths

Elysium's Synthetic Opioid Overdose Prevention and Reversal (SOOPR™) technology designed specifically to combat oral fentanyl overdose LYONS, Colo., June 11, 2025 /PRNewswire/ -- Elysium Therapeutics, an emerging biopharmaceutical company developing treatments specifically designed to rescue and reverse overdoses caused by oral opioids, including synthetic opioids like fentanyl, recently hosted a webcast to educate investors and pharmaceutical leaders on the pressing need to develop overdose rescue therapies designed specifically for synthetic opioids, like fentanyl. Entitled, "Innovating Solutions to Combat Fentanyl Rebound" and led by Greg Sturmer, CEO, the presentation noted that short-acting opioid antagonists like Narcan® and Opvee® are frequently ineffective in the management of synthetic opioid overdoses1, with 20 to 45% of overdose victims initially rescued with naloxone experiencing a re-narcotization event. Sturmer commented: "When fentanyl is taken orally, individuals can face a danger zone, a period of respiratory depression that can last six to eight hours, which far outlasts the window provided by currently available rescue agents that only last, at most, 30 minutes. The result is nearly half of those initially given a dose of today's rescue medications experience a rebound or re-narcotization event, which can lead to a hypoxic brain injury, cardiovascular toxicity or death." To address this critical shortcoming, Elysium designed its Synthetic Opioid Overdose Prevention and Reversal (SOOPR™) technology to be both faster acting and with the potential to offer overdose protection out to approximately 24-hours. Additionally, Elysium designed SOOPR with an intramuscular route of administration, which grants more reliable dosing, in comparison to intranasal administration, which can lead to partial and uncertain dosing in high stress settings. Sturmer added: "SOOPR was designed specifically for synthetic opioids, which are now the number one killer of adults aged 18 to 45 in the U.S. The need for a rapid-acting, long-duration reversal agent, such as SOOPR, is extreme given its potential to reduce the likelihood of hypoxic brain injury, cardiovascular events, re-narcotization, and death. Recognizing this opportunity, Elysium is planning to rapidly advance the SOOPR clinical program along a timeline that could enable the technology to reach the market in the next two to three years." About SOOPR™ (Synthetic Opioid Overdose Prevention and Rescue) SOOPR (Synthetic Opioid Overdose Prevention and Reversal) is a rapid-onset, long-acting rescue agent specifically designed to address overdose from synthetic opioids, including oral fentanyl. SOOPR utilizes a proprietary long-acting naloxone reversal formulation with faster onset kinetics versus Narcan® delivered via long-acting injection (LAI) technology. The technology is designed to rapidly restore respiration and provide 18 – 24 hours of effective opioid blockade to minimize the risk of re-narcotization, while also providing protection from same-day re-use of opioids. SOOPR has been endorsed by first responders and OUD treatment professionals as the effective solution urgently needed to address the global opioid overdose epidemic. About Elysium Therapeutics Elysium is an emerging biopharmaceutical company developing treatments specifically designed to rescue and reverse overdoses caused by oral synthetic opioids, including fentanyl. Elysium is working to establish new standards of safety in the opioid industry by developing SMART™ (Safer Medicines Alleviate Risks and Trauma) products, first- and best-in-class medicines that address the limitations and dangers associated with opioids and overdose rescue agents to reduce suffering from opioid-use disorder, opioid overdose, and acute pain. Elysium's lead technology, SOOPR™ (Synthetic Opioid Overdose Prevention and Reversal), is a long-acting opioid antagonist specifically designed to address oral synthetic opioid, including fentanyl, overdose. Tens of thousands of unnecessary overdose deaths each year exemplifies the critical shortcomings of currently available rescue agents, including naloxone and nalmefene. In addition, Elysium is developing oral-overdose protected (O2P™) hydrocodone for the treatment of moderate-to-severe acute pain. For more information, please visit . ¹ Rachael Rzasa Lynn and JL Galinkin Ther Adv Drug Saf 2018, Vol. 9(1) 63–88. SOURCE Elysium Therapeutics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

03 Jun 2025

·www.prnewswire.com

Nest Health Launches Home-Based Substance Use Disorder Program to Expand Access to Life-Saving Treatment

NEW ORLEANS, June 3, 2025 /PRNewswire/ -- Nest Health, the leading family-centered, home-based healthcare provider for high-risk families, today announced the launch of Nest Rooted Recovery, a new Medication for Opioid Use Disorder (MOUD) program. The program brings evidence-based addiction treatment into the home while integrating ongoing medical, behavioral, and social care for the entire family. Unlike traditional programs addressing substance use disorder or mental health in isolation, Nest Rooted Recovery is embedded within Nest's fully integrated care model. Pregnant and non-pregnant adults receive not only life-saving addiction treatment but also continuous access to primary care, chronic condition management, mental health services, and social care — all delivered at home and online by the trusted Nest care team. The need for innovative treatment models is urgent. The CDC reports that in 2022, nearly 108,000 people in the U.S. died from drug overdoses, with opioids, especially fentanyl, driving the crisis. Yet, fewer than 36% of individuals with opioid use disorder receive any treatment. Nest Health's Rooted Recovery program removes common barriers to care, including transportation, stigma, and fragmented services, by meeting patients where they feel safest: at home. "I'm so proud of this program — it provides much-needed access to treatment into the homes of families who deserve compassionate support, dignity, and a real chance at recovery," said Kelsie Brandt, Chief Clinical Officer at Nest Health. "Our incredible clinical team provides care in the real context of people's lives, always without judgment, with an unwavering commitment to helping our families thrive." Comprehensive, Coordinated In-Home Care for Opioid Use Disorder Nest Rooted Recovery is built on evidence-based clinical protocols and best practices from organizations such as SAMHSA, ACOG, WHO, CDC, and NIDA. The program includes: In-Home Clinical Assessments evaluating opioid dependence severity (DSM-5 criteria), concurrent substance use, infectious diseases, toxicology (including fentanyl), and social determinants of health. Medication Initiation and Monitoring with FDA-approved treatments and medications, primarily buprenorphine/naloxone, following safety-focused protocols to minimize withdrawal symptoms. Pharmacy Coordination ensuring patients have timely access to medications and overdose prevention tools like naloxone. Ongoing Monitoring with frequent provider check-ins during the first 72 hours and education on medication management and emergency response. Seamless Transitions with warm handoffs to long-term recovery partners, including Odyssey House for in-person support and Eleanor Health for telehealth-based care. Ongoing Medical, Mental and Social Care, with Nest continuing to provide recovery support, primary care, sick care, chronic disease management, specialist coordination, and check-ins with mental health specialists — ensuring continuity and checking potential hiccups in recovery early. The Power of Home-Based, Family-Centered Care Nest Health's unique model addresses substance use disorder in the full context of patients' lives. By delivering care in the home, the program not only eliminates logistical barriers but also enables providers to observe and address social and environmental factors that impact health and recovery. Furthermore, Nest's whole-family approach ensures that care is comprehensive, coordinated, and designed to strengthen the family unit. The health of caregivers is deeply intertwined with the health of their children. When a parent is struggling, the effects ripple across the entire family. Addressing substance use and supporting caregiver health not only improves outcomes for the individual but also fosters better health, stability, and future opportunities for their children. For Nest's Medicaid plan partners, this program represents a scalable, high-impact solution that broadens access and improves outcomes across the continuum of care. About Nest Health Nest Health is the first value-based healthcare provider built for families. Nest is making comprehensive medical, social, and behavioral care radically accessible to America's highest risk families through in-home visits and wraparound virtual care. We address the medical, behavioral, and social care needs of families, as a unit. Nest's multidisciplinary and diverse care team delivers longitudinal care at the right time and place to the entire family, addressing the root cause of unnecessarily high hospital utilization and poor-quality outcomes. Increasing member satisfaction and appropriate engagement, Nest's comprehensive care model ultimately reduces the cost of care and improves quality measures. Learn more at . To learn more about the Nest care model, watch this video by HBO Katrina Babies filmmaker Edward Buckles, Jr. Media Contact: Catherine Sanderson Head of Marketing & Communications at Nest Health [email protected] SOURCE Nest Health WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

100 Deals associated with Fentanyl Citrate

External Link

KEGG	Wiki	ATC	Drug Bank
D01399	Fentanyl Citrate	N02AB03 N01AH01	DB00813

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Pain	United States	Adalvo Ltd.	16 Jul 2009
Breakthrough Pain	European Union	Teva Pharmaceuticals Europe BV	04 Apr 2008
Breakthrough Pain	Iceland	Teva Pharmaceuticals Europe BV	04 Apr 2008
Breakthrough Pain	Liechtenstein	Teva Pharmaceuticals Europe BV	04 Apr 2008
Breakthrough Pain	Norway	Teva Pharmaceuticals Europe BV	04 Apr 2008
Cancer Pain	United States	Cephalon, Inc.	04 Nov 1998
Hyperemesis Gravidarum	China	Yichang Humanwell Pharmaceuticals Co., Ltd.	01 Jan 1981
Anesthesia	United States	Rising Pharmaceuticals, Inc.	19 Feb 1968

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Head and Neck Neoplasms	Phase 3	Italy	L. Molteni & C. dei F.lli Alitti Società di Esercizio SpA	01 Sep 2014
Respiratory Insufficiency	Phase 3	-	BioDelivery Sciences International, Inc.	01 Jun 2008
Chronic Pain	Phase 3	United States	Cephalon, Inc.	01 Dec 2006
Neoplasms	Phase 3	-	Cephalon, Inc.	01 Jun 2004
Dyspnea, Paroxysmal	Phase 2	Germany	Teva Branded Pharmaceutical Products R&D, Inc.	01 Mar 2013
Lung Cancer	Phase 2	Germany	Teva Branded Pharmaceutical Products R&D, Inc.	01 Mar 2013
Anemia, Sickle Cell	Phase 2	United States	Cephalon, Inc.	01 Oct 2006
Anemia, Sickle Cell	Phase 2	Canada	Cephalon, Inc.	01 Oct 2006
Anemia, Sickle Cell	Phase 2	Puerto Rico	Cephalon, Inc.	01 Oct 2006
Burns	Phase 2	United States	Cephalon, Inc.	01 Oct 2006

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04230681 (CTgov)	Early Phase 1	Sleep Apnea, Obstructive \| Tonsillitis	189	Hydromorphone (Hydromorphone)	zhrtxkaybo = tulsdhbazl ixgrnpnegm (flpfnyqlqf, nudfrrwlki - nhoxhvxqgz) View more	-	18 Dec 2024
				Fentanyl (Fentanyl)	zhrtxkaybo = lbmboxgtwd ixgrnpnegm (flpfnyqlqf, owgqttmdah - rdvmyyhpno) View more
NCT03435003 (CTgov)	Phase 4	Postoperative Nausea and Vomiting \| Vomiting	83	dexmedetomidine+Total intravenous anesthesia+Fentanyl+scopolamine transdermal+Compazine+sugammadex+Reglan+Propofol+Dexamethasone+Ondansetron+Aprepitant 80 mg Oral Capsule (Intervention Arm)	dccftovqsj = nrrmyoubfp ffavjqhqiz (lbymwqcils, hypyddviee - txllmpefmc) View more	-	14 Feb 2024
				Compazine+sugammadex+Reglan+Sevoflurane+Dexamethasone+desflurane+Ondansetron (Control Arm)	dccftovqsj = casmwlatzl ffavjqhqiz (lbymwqcils, ciqmxlwwls - gqpnhmpqdl) View more
NCT03115151 (CTgov)	Phase 4	Pain	46	Fentanyl+Bupivacaine (Patient-Controlled Epidural Analgesia)	kmmvtdwjjg(fjhmuibvhh) = ydrmweamdp dpkhspzmnm (zjtuiduqmn, 24.69) View more	-	26 Oct 2023
				Hydromorphone (Intravenous Patient-controlled Analgesia)	kmmvtdwjjg(fjhmuibvhh) = usycocoorj dpkhspzmnm (zjtuiduqmn, 25.41) View more
NCT01362998 (CTgov)	Not Applicable	Analgesia	2	morphine (Preservative Free Morphine)	giljmdbsoe(iidyqzcrnm) = dkowhshuoi ufbbcgymum (bpbugbycrx, fusrjymvnx - snzbjtzciy) View more	-	14 Nov 2022
				Fentanyl (Fentanyl Infusion)	fqtqcwuiuu = pyeumgpkjx piejabhdmz (wrbacvdvmy, acruqibnpx - bdzhfervai) View more
NCT03882788 (NDO, CTgov)	Not Applicable	Heart Defects, Congenital \| Maternal anesthesia and analgesia affecting fetus or newborn \| Neurodevelopmental Disorders	153	Fentanyl (Narcotic Based Anesthesia)	rgolbsxbon(sejmaiztmf) = apazmlmmcn cvpcnyacdy (idyzuvzxnd, 10) View more	-	09 May 2022
				Fentanyl+Isoflurane (Volatile Anesthesia)	rgolbsxbon(sejmaiztmf) = watpcsgxqn cvpcnyacdy (idyzuvzxnd, 15) View more
NCT03938857 (DOSE, CTgov)	Phase 1	Critical Illness \| Mechanical ventilation complication	30	Fentanyl (Fen. SOC+Saline Placebo (Bolus+Infusion))	adqadehavl(xtlwraqiko) = ndoqdnqwzc rbjgthlsou (jocqerkpwr, 2.15) View more	-	05 Nov 2021
				dexmedetomidine+Fentanyl (Fen. SOC+Dex.(.5mcg/kg + .25mcg/kg/hr))	adqadehavl(xtlwraqiko) = gsacrynfmb rbjgthlsou (jocqerkpwr, 1.53) View more
NCT02747875 (CV_RCT_M_F, CTgov)	Not Applicable	Pain, Postoperative	26	Fentanyl (Control - Fentanyl)	yjidtftmnr(gukebhhglo) = tuflutiemk qfytarjltz (rdlzzsvkqd, 0.21) View more	-	01 Jun 2021
				Methadone (Treatment - Methadone)	yjidtftmnr(gukebhhglo) = tpfhuilzzf qfytarjltz (rdlzzsvkqd, 0.24) View more
NCT02056288 (CTgov)	Phase 4	Fractures, Bone \| Pain, Postoperative	78	Ropivacaine (Ultrasound Guided Supraclavicular Block)	qynfusvexy(kclpursrwe) = vwfnmpcryc iogtcokqag (hoefqcoqtk, hzwwzecaho - mgccdpprdx) View more	-	21 May 2021
				Fentanyl (IV Opioids)	qynfusvexy(kclpursrwe) = czjwiffqmc iogtcokqag (hoefqcoqtk, ozutjbpnyx - mahfiibvyk) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Fentanyl Citrate

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation